Thirteen patients with herpesvirus infections who were unresponsive to at least 72 h of intermittent acyclovir administration received high-dose continuous infusion. Steady-state concentrations were maintained at between 20 and 98 ,umol/liter. Of 12 patients who had continuous infusion for >5 days, 7 (58%) resolved their infections, as determined by clinical and virologic parameters, suggesting that continuous infusion may succeed in some patients who do not respond to conventional therapy.
Acyclovir is a purine nucleoside with in vitro activity against herpes simplex virus (HSV), varicella-zoster virus, Epstein-Barr virus (EBV) , and cytomegalovirus (CMV) (1) . The drug has been shown to be of clinical benefit when administered topically, orally, or parenterally for the prophylaxis and treatment of certain herpesvirus infections (1) . While acyclovir is conventionally given by intermittent oral or intravenous routes, the method of administration that best inhibits viral replication is not known. This report describes the use of high-dose acyclovir given by continuous intravenous infusion to 13 patients with serious herpesvirus infections.
Patients hospitalized at the University of Minnesota Hospital were eligible for this study if they (i) had serious, systemic, life-threatening herpesvirus infections; (ii) had received at least 72 h of intermittent oral or intravenous acyclovir; and (iii) were judged by the attending physicians to have had poor responses to conventional, intermittent acyclovir administration. Clinical indicators of poor response included continued fever and weakness in CMVinfected individuals, progression of mucocutaneous lesions in HSV-infected individuals, and continued fever or lymphadenopathy in EBV-infected individuals.
The acyclovir dosing regimen for continuous infusion was designed by using a two-compartment pharmacokinetic model (5) , with acyclovir elimination defined as a function of creatinine clearance (CLCR). Nominal values of the pharmacokinetic parameters used for simulation of concentration in plasma and dosage regimen design were as follows: volume of distribution of the central compartment, 0.32 liter/kg of body weight, and intercompartmental rate constants of 1.3 h-1 (k12) and 0.8 h-1 (k21 (Fig. 1) . To optimize therapy, the administration rate was subsequently increased in patients 2, 3, 4, 10, and 12. Acyclovir CL (Fig.  2) ranged from 71 to 555 ml/min per 1.73 m2 and correlated well with CLCR in these patients (r = 0.94). The only dose-limiting adverse event observed was neutropenia (abThe intermittent administration of parenteral acyclovir has solute count, <1,000/mm3), which occurred in patients 5, 9,
shown widespread safety and utility in the treatment of and 11. No patient experienced renal insufficiency as a result herpes-group viral infections. However, the pharmacodyof these high levels of acyclovir. Urine output remained namic relationship between inhibition of viral replication and above 0.5 ml/mg of drug administered in all patients except exposure to acyclovir is essentially unknown, as is the patient 2, who was in acute renal failure and undergoing relationship between acyclovir concentrations in plasma continuous peritoneal dialysis (0.5 to 1 Our study also suggests that acyclovir continuous infusion discontinued. Patient 5 was not considered evaluable bemay have some clinical usefulness. Two of five evaluable cause neutropenia forced discontinuation of the continuouspatients with CMV infection and three of three patients with infusion regimen 2 days after initiation.
HSV infection were judged improved on the basis of cessa- tion of viral shedding and clinical resolution (which meant cessation of fever and weakness for those with CMV disease and healing of mucocutaneous lesions for those with HSV disease). EBV disease was considered improved in two of four patients: one patient had resolution of fever and decreased lymphadenopathy by computerized tomography scan, and the other had marked regression of hepatomegaly and lymphadenopathy; Our pharmacokinetic model for acyclovir dosing performed well, accommodating the wide range of renal function present in these patients. The relationship between acyclovir CL and CLCR observed in our study is consistent with that described by Blum et al. (3) . Acyclovir concentrations in plasma were achieved and maintained within the desired targeted limits.
All three patients infected with HSV had isolates that were deficient in thymidine kinase activity, with 50% inhibitory levels (ID50s) of acyclovir exceeding 40 pLmol/liter. Sensitive HSV isolates had ID50 of <8 pmol/liter (6) useful in treating infections due to acyclovir-resistant HSV, such as those described in this report and by others (2, 10) . Additionally, continuous infusion may be useful in therapy of B-cell lymphoproliferation induced by EBV. Acyclovir has been previously described as beneficial when administered in the polyclonal phase of the disease (9) . The use of acyclovir for treatment of CMV remains controversial. The apparent usefulness of ganciclovir, however, probably limits further investigation of acyclovir, at least as a treatment for CMV (7) . Lastly, continuous infusion of acyclovir may represent a treatment approach for patients who have severe viral infections not responding to conventional administration of the drug and are at risk for the sequelae, such as neurotoxicity, of alternative agents (8) . The potential risks of continuous infusion appear to be nephrotoxicity and neutropenia. Nephrotoxicity (not observed in this study) can be minimized by close attention to dose, renal function, and hydration status of the patient. Concomitant administration of other agents known to cause neutropenia should be avoided or done with extreme caution if continuous infusion is attempted. Finally, acyclovir continuous infusion should be used only by centers able to closely monitor the virologic status of their patients and periodically determine the circulating concentration of the drug.
